Showing 5241-5250 of 8786 results for "".
- Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2019 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/calling-all-students-ortho-dermatologics-now-accepting-applications-for-the-2019-aspire-higher-scholarship-program/2459978/Ortho Dermatologics is accepting applications for its 2019 Aspire Higher scholarship program, which will award $90,000 total in scholarships to nine students who have been treated for a dermatologic condition. Students can apply for the Aspire Higher scholarship through April 26, 2
- L'Oréal Partners with uBiome to Advance New Research on the Skin's Microbiomehttps://practicaldermatology.com/news/loral-partners-with-ubiome-to-advance-new-research-on-the-skins-microbiome/2459980/L'Oréal’s tech Incubator is joining forces with uBiome, a Silicon Valley-based microbiome research venture. The partnership was announced at L'Oréal's "Know Your Sk
- Patricia Altavilla Named New CEO at Suneva Medicalhttps://practicaldermatology.com/news/patricia-altavilla-named-new-ceo-at-suneva-medical/2459982/Patricia Altavilla is the new Chief Executive Officer of Suneva® Medical, Inc. An industry vet, Altavilla began her career at Mentor Corporation, serving as Vice President of International Sales and Worldwide Marketing. For n
- New HelloBello Baby Care Products Make a Big Splash at Walmarthttps://practicaldermatology.com/news/new-hellobello-baby-care-products-make-a-big-splash-at-walmart/2459983/Walmart is rolling out a host of new products from HelloBello, an affordable plant-based baby care line co-founded by Kristen Bell and Dax Shepard. Hello Bello will launch with 10 products including diapers, wipes, shampoo & body wash, bubb
- Almirall: Positive Data for KX2-391 for AKs; ThermiGen to be Divestedhttps://practicaldermatology.com/news/almirall-positive-data-for-kx2-391-for-aks-thermigen-to-be-divested/2459986/Results from two Phase III studies of KX2-391, also known as KX-01 ointment, in the treatment of actinic keratosis show positive results. The findings have been presented at the 2019 American Academy of Dermatology Annual Meeting in Washington, DC and were
- Pulse Biosciences, Inc's CellFX System Performs Well in Sebaceous Hyperplasia Studyhttps://practicaldermatology.com/news/pulse-biosciences-incs-cellfx-system-performs-well-in-sebaceous-hyperplasia-study/2459987/Pulse Biosciences, Inc’s CellFX Nano-Pulse Stimulation system cleared more than 90 percent of sebaceous hyperplasia (SH) lesions in a study presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,
- Dr. George J. Hruza Named New AAD Presidenthttps://practicaldermatology.com/news/dr-george-j-hruza-named-new-aad-president/2459881/St. Louis dermatologist George J. Hruza, MD, MBA, FAAD, is set to begin his one-year term as president of the American Academy of Dermatology (AAD) at the conclusion of the 2019 AAD Annual Meeting in Washington. “The health care landscape is evolving, and it’s important for de
- FDA Approves Janssen's Tremfya One-Presshttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-one-press/2459882/The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson
- Cutera to Unveil excel V+ Next Generation Laser Platform at AAD Annual Meetinghttps://practicaldermatology.com/news/cutera-to-unveil-excel-v-next-generation-laser-platform-at-aad-annual-meeting/2459888/Cutera, Inc. has launched its excel V+ laser platform, which the company describes as a technological advancement that includes 50 percent more power and treatment speed, optimized delivery systems and parameters for treating vascular lesions and pigmentation concerns. Cutera will unveil the exce